Clinical Trials Directory

Trials / Completed

CompletedNCT01529645

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years

Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
420 (actual)
Sponsor
Novartis Vaccines · Industry
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

This study will evaluate the safety and efficacy of 9 different vaccines containing aP (acellular pertussis) and TdaP (acellular pertussis, tetanus and diphtheria) in healthy subjects 18 to 40 years of age.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAcellular pertussis vaccineAcellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
BIOLOGICALTetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
BIOLOGICALLicensed TdaP booster vaccineLicenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
BIOLOGICALDiphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
OTHERSaline solutionSubjects received one injection of saline solution at one month after vaccination.

Timeline

Start date
2012-03-01
Primary completion
2012-07-01
Completion
2013-07-01
First posted
2012-02-09
Last updated
2016-04-04
Results posted
2014-09-18

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01529645. Inclusion in this directory is not an endorsement.

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Hea (NCT01529645) · Clinical Trials Directory